^Stone NJ, Robinson JG, Lichtenstein AH, et al. (June 2014). “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Circulation129 (25 Suppl 2): S1–45. doi:10.1161/01.cir.0000437738.63853.7a. PMID24222016.
^Catapano AL, Reiner Z, De Backer G, et al. (July 2011). “ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)”. Atherosclerosis217 (1): 3–46. PMID21882396.
^Teramoto T, Sasaki J, Ishibashi S, et al. (2013). “Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version”. J. Atheroscler. Thromb.20 (6): 517–23. PMID23665881.
^“An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report”. J Clin Lipidol8 (1): 29–60. (2014). doi:10.1016/j.jacl.2013.12.005. PMID24528685.
^Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi: 10.1056/NEJMoa1410489.
^U.S. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services. Page last updated: 27 October 2014 Medline Plus: Ezetimibe